Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).
1 finding from 1 review
Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).
1 finding from 1 review
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with CQ (low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P probably leads to lower effective treatment of the blood stage parasite As assessed by:… compared with alternative ACTs (moderate certainty).
1 finding from 1 review
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with alternative ACTs (low certainty).
1 finding from 1 review